Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1988 2
1993 1
2007 1
2008 3
2009 1
2010 2
2011 2
2012 4
2013 6
2017 1
2018 2
2019 4
2020 3
2021 3
2022 9
2023 12
2024 21
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G; REACH2 Trial Group. Zeiser R, et al. N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22. N Engl J Med. 2020. PMID: 32320566 Clinical Trial.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT.
Sanz J, Labopin M, Choi G, Kulagin A, Peccatori J, Vydra J, Reményi P, Versluis J, Rovira M, Blaise D, Labussière-Wallet H, Montoro J, Sica S, Meijer E, Itälä-Remes M, Schaap N, Bulabois CE, Piemontese S, Mohty M, Ciceri F. Sanz J, et al. Among authors: vydra j. Blood. 2024 Jun 13;143(24):2534-2543. doi: 10.1182/blood.2023023697. Blood. 2024. PMID: 38657278
Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight.
Schetelig J, Baldauf H, Heidenreich F, Hoogenboom JD, Spellman SR, Kulagin A, Schroeder T, Sengeloev H, Dreger P, Forcade E, Vydra J, Wagner-Drouet EM, Choi G, Paneesha S, Miranda NAA, Tanase A, de Wreede LC, Lange V, Schmidt AH, Sauter J, Fein JA, Bolon YT, He M, Marsh SGE, Gadalla SM, Paczesny S, Ruggeri A, Chabannon C, Fleischhauer K. Schetelig J, et al. Among authors: vydra j. Front Immunol. 2024 Apr 2;15:1350470. doi: 10.3389/fimmu.2024.1350470. eCollection 2024. Front Immunol. 2024. PMID: 38629074 Free PMC article.
Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms.
Chalandon Y, Eikema DJ, Moiseev I, Ciceri F, Koster L, Vydra J, Passweg J, Rovira M, Ozcelik T, Gedde-Dahl T, Kröger N, Potter V, Yakoub-Agha I, Rambaldi A, Itälä-Remes M, Tanase A, Onida F, Gurnari C, Scheid C, Drozd-Sokolowska J, Raj K, McLornan DP, Robin M. Chalandon Y, et al. Among authors: vydra j. Blood Adv. 2024 Sep 24;8(18):4792-4802. doi: 10.1182/bloodadvances.2024013468. Blood Adv. 2024. PMID: 39008719 Free PMC article.
Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT.
Sanz J, Labopin M, Blaise D, Raiola AM, Busca A, Vydra J, Tischer J, Chevallier P, Bramanti S, Fanin R, Socié G, Forcade E, Kröger N, Koc Y, Itäla-Remes M, Zecca M, Nagler A, Brissot E, Spyridonidis A, Bazarbachi A, Giebel S, Piemontese S, Mohty M, Ciceri F. Sanz J, et al. Among authors: vydra j. Blood Adv. 2024 May 28;8(10):2332-2341. doi: 10.1182/bloodadvances.2023012133. Blood Adv. 2024. PMID: 38429091 Free PMC article.
Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A, Ngoya M, Galimard JE, Labopin M, Blau IW, Kröger N, Gedde-Dahl T, Schroeder T, Burns D, Salmenniemi U, Rambaldi A, Choi G, Peffault de Latour R, Vydra J, Sengeloev H, Eder M, Mielke S, Forcade E, Kulagin A, Ciceri F, Mohty M. Nagler A, et al. Among authors: vydra j. Am J Hematol. 2024 Sep;99(9):1732-1745. doi: 10.1002/ajh.27383. Epub 2024 Jun 10. Am J Hematol. 2024. PMID: 38856236
Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Devillier R, Galimard JE, Blaise D, Raiola AM, Bramanti S, Grillo G, Pastano R, de Latour RP, Busca A, López-Corral L, Rodríguez AB, Schmid C, Forcade E, Vydra J, Solano C, Bug G, Neubauer A, Charbonnier A, Brissot E, Nagler A, Ciceri F, Mohty M. Devillier R, et al. Among authors: vydra j. Am J Hematol. 2024 Jul;99(7):1250-1256. doi: 10.1002/ajh.27343. Epub 2024 May 23. Am J Hematol. 2024. PMID: 38778766
Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Ye Y, Labopin M, Gérard S, Yakoub-Agha I, Blau IW, Aljurf M, Forcade E, Gedde-Dahl T, Burns D, Vydra J, Halahleh K, Hamladji RM, Bazarbachi A, Nagler A, Brissot E, Li L, Luo Y, Zhao Y, Ciceri F, Huang H, Mohty M, Gorin NC. Ye Y, et al. Among authors: vydra j. Am J Hematol. 2024 Jul;99(7):1290-1299. doi: 10.1002/ajh.27342. Epub 2024 Apr 24. Am J Hematol. 2024. PMID: 38654658
Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide.
Piemontese S, Labopin M, Choi G, Broers AEC, Peccatori J, Meijer E, Van Gorkom G, Rovira M, Pascual Cascon MJ, Sica S, Vydra J, Kulagin A, Spyridonidis A, Nagler A, Bazarbachi A, Savani B, Brissot E, Sanz J, Mohty M, Ciceri F. Piemontese S, et al. Among authors: vydra j. Leukemia. 2024 Sep;38(9):2016-2022. doi: 10.1038/s41375-024-02359-8. Epub 2024 Jul 24. Leukemia. 2024. PMID: 39048722
73 results